Bicara Therapeutics (BCAX) Other Working Capital Changes (2023 - 2026)
Bicara Therapeutics' (BCAX) quarterly Other Working Capital Changes came in at -$270000.0 in Q1 2026, down 83.67% year-on-year from -$1.7 million in Q1 2025, and up 7.53% quarter-over-quarter from -$292000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Other Working Capital Changes (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Other Working Capital Changes history runs 4 years deep, the most recent figure standing at -$270000.0 for Q1 2026.
- On a quarterly basis, Other Working Capital Changes fell 83.67% year-over-year to -$270000.0 in Q1 2026; TTM through Mar 2026 was -$1.1 million, a 52850.0% decrease from a year earlier, with the FY2025 full-year figure at -$932000.0, down 1250.62% from the prior year.
- Other Working Capital Changes advanced to -$270000.0 in Q1 2026 per BCAX's latest filing, from -$292000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $16.6 million in Q4 2024 and bottomed at -$4.1 million in Q1 2025.
- The 4-year median for Other Working Capital Changes is -$2000.0 (2023), against an average of $953900.0.
- Across the five-year window, Other Working Capital Changes jumped 830.0% in 2024 and plunged 340.28% in 2025, its largest moves.
- Year by year, Other Working Capital Changes stood at -$40000.0 in 2023, then soared by 830.0% to $292000.0 in 2024, then sank by 200.0% to -$292000.0 in 2025, then increased by 7.53% to -$270000.0 in 2026.
- Per Business Quant, the three latest BCAX Other Working Capital Changes figures stand at -$270000.0 (Q1 2026), -$292000.0 (Q4 2025), and -$317000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Bicara Therapeutics | 1.68 Bn | 1.68 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -270,000.00 |
| Mar 31, 2026 | -270,000.00 |
| Mar 31, 2026 | -270,000.00 |
| Dec 31, 2025 | -292,000.00 |
| Dec 31, 2025 | -292,000.00 |
| Dec 31, 2025 | -292,000.00 |
| Sep 30, 2025 | -317,000.00 |
| Sep 30, 2025 | -317,000.00 |
| Sep 30, 2025 | -317,000.00 |
| Jun 30, 2025 | -176,000.00 |
| Jun 30, 2025 | -176,000.00 |
| Jun 30, 2025 | -176,000.00 |
| Mar 31, 2025 | -147,000.00 |
| Mar 31, 2025 | -147,000.00 |
| Mar 31, 2025 | -147,000.00 |
| Dec 31, 2024 | 292,000.00 |
| Dec 31, 2024 | 292,000.00 |
| Dec 31, 2024 | 292,000.00 |
| Sep 30, 2024 | -72,000.00 |
| Sep 30, 2024 | -72,000.00 |